Concepts for agonistic targeting of CD40 in immuno-oncology

References

• Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–46. doi:10.1038/nrc3670.
   PubMed Web of Science ®Google Scholar
• Suek N, Campesato LF, Merghoub T, Khalil DN. Targeted APC activation in cancer immunotherapy to enhance the abscopal effect. Front Immunol. 2019;10:604. doi:10.3389/fimmu.2019.00604.
   PubMed Web of Science ®Google Scholar
• Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22:307–28. doi:10.1146/annurev.immunol.22.012703.104533.
   PubMed Web of Science ®Google Scholar
• Korniluk A, Kemona H, Dymicka-Piekarska V. Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol. 2014;35(10):9447–57. doi:10.1007/s13277-014-2407-x.
   PubMed Web of Science ®Google Scholar
• Hamilton TA, Zhao C, Pavicic PG Jr., Datta S. Myeloid colony-stimulating factors as regulators of macrophage polarization. Front Immunol. 2014;5:554. doi:10.3389/fimmu.2014.00554.
   PubMed Web of Science ®Google Scholar
• Mia S, Warnecke A, Zhang XM, Malmstrom V, Harris RA. An optimized protocol for human M2 macrophages using M-CSF and IL-4/IL-10/TGF-beta yields a dominant immunosuppressive phenotype. Scand J Immunol. 2014;79(5):305–14. doi:10.1111/sji.12162.
   PubMed Web of Science ®Google Scholar
• Fujihara C, Williams JA, Watanabe M, Jeon H, Sharrow SO, Hodes RJ. T cell-B cell thymic cross-talk: maintenance and function of thymic B cells requires cognate CD40-CD40 ligand interaction. J Immunol. 2014;193(11):5534–44. doi:10.4049/jimmunol.1401655.
   PubMed Web of Science ®Google Scholar
• Koncz G, Hueber AO. The Fas/CD95 receptor regulates the death of autoreactive B cells and the selection of antigen-specific B cells. Front Immunol. 2012;3:207. doi:10.3389/fimmu.2012.00207.
   PubMed Web of Science ®Google Scholar
• van Zelm MC, Bartol SJ, Driessen GJ, Mascart F, Reisli I, Franco JL, Wolska-Kusnierz B, Kanegane H, Boon L, van Dongen JJ, et al. Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation. J Allergy Clin Immunol. 2014;134(1):135–44. doi:10.1016/j.jaci.2013.11.015.
   PubMed Web of Science ®Google Scholar
• Coler RN, Hudson T, Hughes S, Huang PW, Beebe EA, Orr MT. Vaccination produces CD4 T cells with a novel CD154-CD40-dependent cytolytic mechanism. J Immunol. 2015;195(7):3190–97. doi:10.4049/jimmunol.1501118.
   PubMed Web of Science ®Google Scholar
• Mathieu M, Cotta-Grand N, Daudelin JF, Boulet S, Lapointe R, Labrecque N. CD40-activated B cells can efficiently prime antigen-specific naive CD8+ T cells to generate effector but not memory T cells. PLoS One. 2012;7(1):e30139. doi:10.1371/journal.pone.0030139.
   PubMed Web of Science ®Google Scholar
• Kondo E, Gryschok L, Klein-Gonzalez N, Rademacher S, Weihrauch MR, Liebig T, Shimabukuro-Vornhagen A, Kochanek M, Draube A, von Bergwelt-Baildon MS. CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol. 2009;155(2):249–56. doi:10.1111/j.1365-2249.2008.03820.x.
   PubMed Web of Science ®Google Scholar
• Liebig TM, Fiedler A, Zoghi S, Shimabukuro-Vornhagen A, von Bergwelt-Baildon MS. Generation of human CD40-activated B cells. J Vis Exp. 2009;(32). doi:10.3791/1373.
   PubMedGoogle Scholar
• Wennhold K, Weber TM, Klein-Gonzalez N, Thelen M, Garcia-Marquez M, Chakupurakal G, Fiedler A, Schlosser HA, Fischer R, Theurich S, et al. CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget. 2017;8(17):27740–53. doi:10.18632/oncotarget.7720.
   PubMedGoogle Scholar
• Griffiths KL, Ahmed M, Das S, Gopal R, Horne W, Connell TD, Moynihan KD, Kolls JK, Irvine DJ, Artyomov MN, et al. Targeting dendritic cells to accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy. Nat Commun. 2016;7:13894. doi:10.1038/ncomms13894.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, McMannis JD, Bai Y, Seethammagari MR, Bull JMC, Hawkins V, Dancsak TK, Lapteva N, Levitt JM, Moseley A, et al. Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. Cancer Immunol Immunother. 2017;66(10):1345–57. doi:10.1007/s00262-017-2027-6.
   PubMed Web of Science ®Google Scholar
• Luheshi N, Davies G, Legg J. Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists. Oncoimmunology. 2014;3(2):e27615. doi:10.4161/onci.27615.
   PubMed Web of Science ®Google Scholar
• Nielsen SR, Schmid MC. Macrophages as key drivers of cancer progression and metastasis. Mediators Inflamm. 2017;2017:1–11. doi:10.1155/2017/9624760.
   Web of Science ®Google Scholar
• Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R, Ramwadhdoebe TH, Gorter A, Welters MJ, van Hall T, van der Burg SH. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J Immunol. 2011;187(3):1157–65. doi:10.4049/jimmunol.1100889.
   PubMed Web of Science ®Google Scholar
• Luheshi N, Davies G, Poon E, Wiggins K, McCourt M, Legg J. Th1 cytokines are more effective than Th2 cytokines at licensing anti-tumour functions in CD40-activated human macrophages in vitro. Eur J Immunol. 2014;44(1):162–72. doi:10.1002/eji.201343351.
   PubMed Web of Science ®Google Scholar
• Xue N, Zhou Q, Ji M, Jin J, Lai F, Chen J, Zhang M, Jia J, Yang H, Zhang J, et al. Chlorogenic acid inhibits glioblastoma growth through repolarizating macrophage from M2 to M1 phenotype. Sci Rep. 2017;7:39011. doi:10.1038/srep39011.
   PubMed Web of Science ®Google Scholar
• Byrne KT, Vonderheide RH. CD40 stimulation obviates innate sensors and drives T cell immunity in cancer. Cell Rep. 2016;15(12):2719–32. doi:10.1016/j.celrep.2016.05.058.
   PubMed Web of Science ®Google Scholar
• Novosad J, Holicka M, Novosadova M, Krejsek J, Krcmova I. Rapid onset of ICAM-1 expression is a marker of effective macrophages activation during infection of Francisella tularensis LVS in vitro. Folia Microbiol (Praha). 2011;56(2):149–54. doi:10.1007/s12223-011-0028-y.
   PubMed Web of Science ®Google Scholar
• Roszer T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460. doi:10.1155/2015/816460.
   PubMed Web of Science ®Google Scholar
• Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, Ast O, Giusti AM, Wartha K, Runza V, et al. Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. J Exp Med. 2018;215(3):859–76. doi:10.1084/jem.20171440.
   PubMed Web of Science ®Google Scholar
• Wiehagen KR, Girgis NM, Yamada DH, Smith AA, Chan SR, Grewal IS, Quigley M, Verona RI. Combination of CD40 agonism and CSF-1R blockade reconditions tumor-associated macrophages and drives potent antitumor immunity. Cancer Immunol Res. 2017;5(12):1109–21. doi:10.1158/2326-6066.CIR-17-0258.
   PubMed Web of Science ®Google Scholar
• Bugajska U, Georgopoulos NT, Southgate J, Johnson PW, Graber P, Gordon J, Selby PJ, Trejdosiewicz LK. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst. 2002;94(18):1381–95. doi:10.1093/jnci/94.18.1381.
   PubMed Web of Science ®Google Scholar
• Hill KS, Errington F, Steele LP, Merrick A, Morgan R, Selby PJ, Georgopoulos NT, O’Donnell DM, Melcher AA. OK432-activated human dendritic cells kill tumor cells via CD40/CD40 ligand interactions. J Immunol. 2008;181(5):3108–15. doi:10.4049/jimmunol.181.5.3108.
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Lum H, Berke G, Paulnock DM, Sondel PM, Rakhmilevich AL. CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol. 2005;174(10):6013–22. doi:10.4049/jimmunol.174.10.6013.
   PubMed Web of Science ®Google Scholar
• Schiza A, Wenthe J, Mangsbo S, Eriksson E, Nilsson A, Totterman TH, Loskog A, Ullenhag G. Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients. J Transl Med. 2017;15(1):79. doi:10.1186/s12967-017-1182-z.
   PubMedGoogle Scholar
• Byrd JC, Kipps TJ, Flinn IW, Cooper M, Odenike O, Bendiske J, Rediske J, Bilic S, Dey J, Baeck J, et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(11):2136–42. doi:10.3109/10428194.2012.681655.
   PubMed Web of Science ®Google Scholar
• Xu W, Li Y, Yuan WW, Yin Y, Song WW, Wang Y, Huang QQ, Zhao WH, Wu JQ. Membrane-bound CD40L promotes senescence and initiates senescence-associated secretory phenotype via NF-kappaB activation in lung adenocarcinoma. Cell Physiol Biochem. 2018;48(4):1793–803. doi:10.1159/000492352.
   PubMedGoogle Scholar
• Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol. 2005;23:23–68. doi:10.1146/annurev.immunol.23.021704.115839.
   PubMed Web of Science ®Google Scholar
• Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K, Wajant H. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol. 2009;183(3):1851–61. doi:10.4049/jimmunol.0802597.
   PubMed Web of Science ®Google Scholar
• Wajant H. Principles of antibody-mediated TNF receptor activation. Cell Death Differ. 2015;22(11):1727–41. doi:10.1038/cdd.2015.109.
   PubMed Web of Science ®Google Scholar
• Mayes PA, Hance KW, Hoos A. The promise and challenges of immune agonist antibody development in cancer. Nat Rev Drug Discov. 2018;17(7):509–27. doi:10.1038/nrd.2018.75.
   PubMed Web of Science ®Google Scholar
• Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009;229(1):152–72. doi:10.1111/j.1600-065X.2009.00782.x.
   PubMed Web of Science ®Google Scholar
• Seigner J, Basilio J, Resch U, de Martin R. CD40L and TNF both activate the classical NF-kappaB pathway, which is not required for the CD40L induced alternative pathway in endothelial cells. Biochem Biophys Res Commun. 2018;495(1):1389–94. doi:10.1016/j.bbrc.2017.11.160.
   PubMed Web of Science ®Google Scholar
• An HJ, Kim YJ, Song DH, Park BS, Kim HM, Lee JD, Paik SG, Lee JO, Lee H. Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation. J Biol Chem. 2011;286(13):11226–35. doi:10.1074/jbc.M110.208215.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH. The immune revolution: a case for priming, not checkpoint. Cancer Cell. 2018;33(4):563–69. doi:10.1016/j.ccell.2018.03.008.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res. 2013;19(5):1035–43. doi:10.1158/1078-0432.CCR-12-2064.
   PubMed Web of Science ®Google Scholar
• Beatty GL, Li Y, Long KB. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther. 2017;17(2):175–86. doi:10.1080/14737140.2017.1270208.
   PubMed Web of Science ®Google Scholar
• Wold ED, Smider VV, Felding BH. Antibody Therapeutics in Oncology. Immunotherapy (Los Angel). 2016;2(1). doi:10.4172/2471-9552.1000108.
   PubMedGoogle Scholar
• Heath AW, Wu WW, Howard MC. Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur J Immunol. 1994;24(8):1828–34. doi:10.1002/eji.1830240816.
   PubMed Web of Science ®Google Scholar
• Bjorck P, Paulie S. CD40 antibodies defining distinct epitopes display qualitative differences in their induction of B-cell differentiation. Immunology. 1996;87(2):291–95. doi:10.1046/j.1365-2567.1996.428508.x.
   PubMed Web of Science ®Google Scholar
• Bankert KC, Oxley KL, Smith SM, Graham JP, de Boer M, Thewissen M, Simons PJ, Bishop GA. Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40. J Immunol. 2015;194(9):4319–27. doi:10.4049/jimmunol.1402903.
   PubMed Web of Science ®Google Scholar
• Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O’Brien L, Mockridge CI, French RR, et al. Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies. Cancer Cell. 2018;33(4):664–675.e4. doi:10.1016/j.ccell.2018.02.009.
   PubMed Web of Science ®Google Scholar
• Dahan R, Barnhart BC, Li F, Yamniuk AP, Korman AJ, Ravetch JV. Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcgammaR engagement. Cancer Cell. 2016;29(6):820–31. doi:10.1016/j.ccell.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011;333(6045):1030–34. doi:10.1126/science.1206954.
   PubMed Web of Science ®Google Scholar
• Collins DM, O’Donovan N, McGowan PM, O’Sullivan F, Duffy MJ, Crown J. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines. Ann Oncol. 2012;23(7):1788–95. doi:10.1093/annonc/mdr484.
   PubMed Web of Science ®Google Scholar
• Burris HA, Infante JR, Ansell SM, Nemunaitis JJ, Weiss GR, Villalobos VM, Sikic BI, Taylor MH, Northfelt DW, Carson WE 3rd, et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors. J Clin Oncol. 2017;35(18):2028–36. doi:10.1200/JCO.2016.70.1508.
   PubMed Web of Science ®Google Scholar
• Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood. 1997;90:2188–95.
   PubMed Web of Science ®Google Scholar
• Vitale LA, Thomas LJ, He LZ, O’Neill T, Widger J, Crocker A, Sundarapandiyan K, Storey JR, Forsberg EM, Weidlick J, et al. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy. Cancer Immunol Immunother. 2019;68(2):233–45. doi:10.1007/s00262-018-2267-0.
   PubMed Web of Science ®Google Scholar
• Irenaeus SMM, Nielsen D, Ellmark P, Yachnin J, Deronic A, Nilsson A, Norlen P, Veitonmaki N, Wennersten CS, Ullenhag GJ. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int J Cancer. 2019;145:1189–99. doi:10.1002/ijc.32141.
   PubMed Web of Science ®Google Scholar
• Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP, Torigian DA, George SM, Stelekati E, Chen F, et al. Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology. 2018;7(10):e1468956. doi:10.1080/2162402X.2018.1468956.
   PubMed Web of Science ®Google Scholar
• Zafar S, Parviainen S, Siurala M, Hemminki O, Havunen R, Tahtinen S, Bramante S, Vassilev L, Wang H, Lieber A, et al. Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. Oncoimmunology. 2017;6(2):e1265717. doi:10.1080/2162402X.2016.1265717.
   PubMed Web of Science ®Google Scholar
• Saxena M, Bhardwaj N. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines. Curr Opin Immunol. 2017;47:35–43. doi:10.1016/j.coi.2017.06.003.
   PubMed Web of Science ®Google Scholar
• Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168–82. doi:10.1038/nri.2017.131.
   PubMed Web of Science ®Google Scholar
• Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359(6372). doi:10.1126/science.aan4672.
   PubMed Web of Science ®Google Scholar
• Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez AV, Curran KJ, Daniyan AF, Brentjens RJ. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell. 2019;35(3):473–488.e6. doi:10.1016/j.ccell.2019.02.006.
   PubMed Web of Science ®Google Scholar
• Singh M, Vianden C, Cantwell MJ, Dai Z, Xiao Z, Sharma M, Khong H, Jaiswal AR, Faak F, Hailemichael Y, et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017;8(1):1447. doi:10.1038/s41467-017-01572-7.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Milenova I, Wenthe J, Moreno R, Alemany R, Loskog A. IL-6 signaling blockade during CD40-mediated immune activation favors antitumor factors by reducing TGF-beta, collagen type I, and PD-L1/PD-1. J Immunol. 2019;202(3):787–98. doi:10.4049/jimmunol.1800717.
   PubMed Web of Science ®Google Scholar
• Irenaeus S, Schiza A, Mangsbo SM, Wenthe J, Eriksson E, Krause J, Sundin A, Ahlstrom H, Totterman TH, Loskog A, et al. Local irradiation does not enhance the effect of immunostimulatory AdCD40L gene therapy combined with low dose cyclophosphamide in melanoma patients. Oncotarget. 2017;8(45):78573–87. doi:10.18632/oncotarget.19750.
   PubMedGoogle Scholar
• Richards DM, Marschall V, Billian-Frey K, Heinonen K, Merz C, Redondo Muller M, Sefrin JP, Schroder M, Sykora J, Fricke H, et al. HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcgammaR-binding functionality. J Immunother Cancer. 2019;7(1):191. doi:10.1186/s40425-019-0671-4.
   PubMedGoogle Scholar
• Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R, Fischer C, Branschadel M, Abhari BA, Hohenberger P, et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther. 2013;12(12):2735–47. doi:10.1158/1535-7163.MCT-13-0323.
   PubMed Web of Science ®Google Scholar
• Merz C, Sykora J, Marschall V, Richards DM, Heinonen K, Redondo Muller M, Thiemann M, Schnyder T, Fricke H, Hill O, et al. The hexavalent CD40 agonist HERA-CD40L induces T-cell-mediated antitumor immune response through activation of antigen-presenting cells. J Immunother. 2018;41(9):385–98. doi:10.1097/CJI.0000000000000246.
   PubMed Web of Science ®Google Scholar
• Thiemann M, Richards DM, Heinonen K, Kluge M, Marschall V, Merz C, Redondo Muller M, Schnyder T, Sefrin JP, Sykora J, et al. A single-chain-based hexavalent CD27 agonist enhances T cell activation and induces anti-tumor immunity. Front Oncol. 2018;8:387. doi:10.3389/fonc.2018.00387.
   PubMed Web of Science ®Google Scholar
• Lai N, Min Q, Xiong E, Liu J, Zhang L, Yasuda S, Wang JY. A tetrameric form of CD40 ligand with potent biological activities in both mouse and human primary B cells. Mol Immunol. 2019;105:173–80. doi:10.1016/j.molimm.2018.11.018.
   PubMed Web of Science ®Google Scholar
• Yamniuk AP, Suri A, Krystek SR, Tamura J, Ramamurthy V, Kuhn R, Carroll K, Fleener C, Ryseck R, Cheng L, et al. Functional antagonism of human CD40 achieved by targeting a unique species-specific epitope. J Mol Biol. 2016;428(14):2860–79. doi:10.1016/j.jmb.2016.05.014.
   PubMed Web of Science ®Google Scholar
• Baccam M, Bishop GA. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur J Immunol. 1999;29(12):3855–66. doi:10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S.
   PubMed Web of Science ®Google Scholar
• Knorr DA, Dahan R, Ravetch JV. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc Natl Acad Sci U S A. 2018;115(43):11048–53. doi:10.1073/pnas.1810566115.
   PubMed Web of Science ®Google Scholar
• Byrne KT, Leisenring NH, Bajor DL, Vonderheide RH. CSF-1R-dependent lethal hepatotoxicity when agonistic CD40 antibody is given before but not after chemotherapy. J Immunol. 2016;197(1):179–87. doi:10.4049/jimmunol.1600146.
   PubMed Web of Science ®Google Scholar
• Medina-Echeverz J, Ma C, Duffy AG, Eggert T, Hawk N, Kleiner DE, Korangy F, Greten TF. Systemic agonistic anti-CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver damage. Cancer Immunol Res. 2015;3(5):557–66. doi:10.1158/2326-6066.CIR-14-0182.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25(7):876–83. doi:10.1200/JCO.2006.08.3311.
   PubMed Web of Science ®Google Scholar
• Fransen MF, Sluijter M, Morreau H, Arens R, Melief CJ. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17(8):2270–80. doi:10.1158/1078-0432.CCR-10-2888.
   PubMed Web of Science ®Google Scholar
• Kedl RM, Jordan M, Potter T, Kappler J, Marrack P, Dow S. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A. 2001;98(19):10811–16. doi:10.1073/pnas.191371898.
   PubMed Web of Science ®Google Scholar
• Ishihara J, Ishihara A, Potin L, Hosseinchi P, Fukunaga K, Damo M, Gajewski TF, Swartz MA, Hubbell JA. Improving efficacy and safety of agonistic anti-CD40 antibody through extracellular matrix affinity. Mol Cancer Ther. 2018;17(11):2399–411. doi:10.1158/1535-7163.MCT-18-0091.
   PubMed Web of Science ®Google Scholar
• Lu L, Liu N, Fan K, Zhang G, Li C, Yan Y, Liu T, Fu WH. A tetravalent single chain diabody (CD40/HER2) efficiently inhibits tumor proliferation through recruitment of T cells and anti-HER2 functions. Mol Immunol. 2019;109:149–56. doi:10.1016/j.molimm.2019.03.001.
   PubMed Web of Science ®Google Scholar
• Fellermeier-Kopf S, Gieseke F, Sahin U, Muller D, Pfizenmaier K, Kontermann RE. Duokines: a novel class of dual-acting co-stimulatory molecules acting in cis or trans. Oncoimmunology. 2018;7(9):e1471442. doi:10.1080/2162402X.2018.1471442.
   PubMed Web of Science ®Google Scholar
• Dahlen E, Veitonmaki N, Norlen P. Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines Immunother. 2018;6(1):3–17. doi:10.1177/2515135518763280.
   PubMedGoogle Scholar
• Qu X, Felder MA, Perez Horta Z, Sondel PM, Rakhmilevich AL. Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model. Int Immunopharmacol. 2013;17(4):1141–47. doi:10.1016/j.intimp.2013.10.019.
   PubMed Web of Science ®Google Scholar
• Zhang JQ, Zeng S, Vitiello GA, Seifert AM, Medina BD, Beckman MJ, Loo JK, Santamaria-Barria J, Maltbaek JH, Param NJ, et al. Macrophages and CD8(+) T cells mediate the antitumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors. Cancer Immunol Res. 2018;6(4):434–47. doi:10.1158/2326-6066.CIR-17-0345.
   PubMed Web of Science ®Google Scholar
• Rech AJ, Dada H, Kotzin JJ, Henao-Mejia J, Minn AJ, Twyman-Saint Victor C, Vonderheide RH. Radiotherapy and CD40 activation separately augment immunity to checkpoint blockade in cancer. Cancer Res. 2018;78(15):4282–91. doi:10.1158/0008-5472.CAN-17-3821.
   PubMed Web of Science ®Google Scholar
• Yasmin-Karim S, Bruck PT, Moreau M, Kunjachan S, Chen GZ, Kumar R, Grabow S, Dougan SK, Ngwa W. Radiation and local anti-CD40 generate an effective in situ vaccine in preclinical models of pancreatic cancer. Front Immunol. 2018;9:2030. doi:10.3389/fimmu.2018.02030.
   PubMed Web of Science ®Google Scholar
• Ward-Kavanagh LK, Kokolus KM, Cooper TK, Lukacher AE, Schell TD. Combined sublethal irradiation and agonist anti-CD40 enhance donor T cell accumulation and control of autochthonous murine pancreatic tumors. Cancer Immunol Immunother. 2018;67(4):639–52. doi:10.1007/s00262-018-2115-2.
   PubMed Web of Science ®Google Scholar
• Ma HS, Poudel B, Torres ER, Sidhom JW, Robinson TM, Christmas B, Scott B, Cruz K, Woolman S, Wall VZ, et al. A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol Res. 2019;7:428–42. doi:10.1158/2326-6066.CIR-18-0061.
   PubMed Web of Science ®Google Scholar
• Xiong H, Mittman S, Rodriguez R, Moskalenko M, Pacheco-Sanchez P, Yang Y, Nickles D, Cubas R. Anti-PD-L1 treatment results in functional remodeling of the macrophage compartment. Cancer Res. 2019;79:1493–506. doi:10.1158/0008-5472.CAN-18-3208.
   PubMed Web of Science ®Google Scholar
• Luheshi NM, Coates-Ulrichsen J, Harper J, Mullins S, Sulikowski MG, Martin P, Brown L, Lewis A, Davies G, Morrow M, et al. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. Oncotarget. 2016;7(14):18508–20. doi:10.18632/oncotarget.7610.
   PubMedGoogle Scholar
• Ngiow SF, Young A, Blake SJ, Hill GR, Yagita H, Teng MW, Korman AJ, Smyth MJ. Agonistic CD40 mAb-driven IL12 reverses resistance to anti-PD1 in a T-cell-rich tumor. Cancer Res. 2016;76(21):6266–77. doi:10.1158/0008-5472.CAN-16-2141.
   PubMed Web of Science ®Google Scholar
• Sorensen MR, Holst PJ, Steffensen MA, Christensen JP, Thomsen AR. Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine. 2010;28(41):6757–64. doi:10.1016/j.vaccine.2010.07.066.
   PubMed Web of Science ®Google Scholar
• Chonan M, Saito R, Shoji T, Shibahara I, Kanamori M, Sonoda Y, Watanabe M, Kikuchi T, Ishii N, Tominaga T. CD40/CD40L expression correlates with the survival of patients with glioblastomas and an augmentation in CD40 signaling enhances the efficacy of vaccinations against glioma models. Neuro Oncol. 2015;17(11):1453–62. doi:10.1093/neuonc/nov090.
   PubMed Web of Science ®Google Scholar
• Liu C, Lewis CM, Lou Y, Xu C, Peng W, Yang Y, Gelbard AH, Lizee G, Zhou D, Overwijk WW, et al. Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012;35(3):276–82. doi:10.1097/CJI.0b013e31824e7f43.
   PubMed Web of Science ®Google Scholar
• Stromnes IM, Burrack AL, Hulbert A, Bonson P, Black C, Brockenbrough JS, Raynor JF, Spartz EJ, Pierce RH, Greenberg PD, et al. Differential effects of depleting versus programming tumor-associated macrophages on engineered T cells in pancreatic ductal adenocarcinoma. Cancer Immunol Res. 2019;7:977–89. doi:10.1158/2326-6066.CIR-18-0448.
   PubMed Web of Science ®Google Scholar